Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer

• Drug: Epirubicin with Cyclophosphamide, followed by a Taxane
  

  Epirubicin = 90 mg/m2 Cyclophosphamide = 600 mg/m2

  Followed by a taxane; paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2

  Other Name: Epirubicin, ellence,
• Drug: Epirubicin with a Taxane
  

  Epirubicin = 75 mg/m2 per cycle

  Taxane = paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2

  Other Name: Epirubicin, ellence,

• Experimental: B
  

  ET (8 cycles)

  T = docetaxel or paclitaxel

  Intervention: Drug: Epirubicin with a Taxane
• Experimental: A
  

  EC (4 cycles) followed by T (4 cycles) for a total of 8 cycles

  T = docetaxel or paclitaxel

  Intervention: Drug: Epirubicin with Cyclophosphamide, followed by a Taxane

Inclusion Criteria:

• Breast Cancer Stage T1-3, N1, M0
• Suitable candidate for anthracycline-containing adjuvant chemotherapy

Exclusion Criteria:

• Evidence of residual tumor following surgery, or metastatic disease
• Received prior therapy for breast cancer